Evaxion extends phase 2 trial with personalized cancer vaccine evx-01 to further enhance clinical data package

Copenhagen, denmark, february 25, 2025 - evaxion biotech a/s (nasdaq: evax) (“evaxion”), a clinical-stage techbio company specializing in developing ai-immunology™ powered vaccines, will further enhance the data package from its ongoing phase 2 trial with the company's lead asset evx-01 by extending the trial from two to three years. designed with evaxion's ai-immunology™ platform, evx-01 is a personalized cancer vaccine being developed as a treatment for advanced melanoma (skin cancer).
EVAX Ratings Summary
EVAX Quant Ranking